ZYMEWORKS INC (ZYME) Stock Price, Quote, News and Overview
NASDAQ:ZYME - Nasdaq - US98985Y1082 - Common Stock - Currency: USD
ZYME Quote, Performance and Key Statistics
ZYMEWORKS INC
NASDAQ:ZYME (1/24/2025, 5:02:25 PM)
After market: 14.59 0 (0%)14.59
-0.23 (-1.55%)
The current stock price of ZYME is 14.59 USD. In the past month the price increased by 2.17%. In the past year, price increased by 40.29%.
ZYME Latest News, Press Releases and Analysis
Zymeworks in Focus for Insider Activity: Catalysts Ahead
Zymeworks' insider EcoR1 Capital is buying shares ahead of expected catalysts in 2025 that could drive the stock price to multiyear highs.
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025IND applications...
ZYME Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.84 | 300.94B | ||
| AMGN | AMGEN INC | 14.33 | 148.05B | ||
| GILD | GILEAD SCIENCES INC | 21.01 | 115.99B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 862 | 113.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.88 | 74.26B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.47B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.64B | ||
| NTRA | NATERA INC | N/A | 22.13B | ||
| BIIB | BIOGEN INC | 8.95 | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.52B |
Related stock screener links
About ZYME
Company Profile
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company is headquartered in Middletown, Delaware and currently employs 294 full-time employees. The company went IPO on 2019-06-24. The firm is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.
Company Info
ZYMEWORKS INC
108 Patriot Drive, Suite A
Middletown DELAWARE V6H 3V9 US
CEO: Ali Tehrani
Employees: 290
Company Website: https://www.zymeworks.com/
Investor Relations: https://ir.zymeworks.com/
Phone: 13022748744
ZYME FAQ
What is the stock price of ZYME?
The current stock price of ZYME is 14.59 USD.
What is the symbol for ZYMEWORKS INC stock?
The exchange symbol of ZYMEWORKS INC is ZYME and it is listed on the Nasdaq exchange.
On which exchange is ZYME stock listed?
ZYME stock is listed on the Nasdaq exchange.
Is ZYME a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ZYME, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ZYME.
Does ZYME stock pay dividends?
ZYME does not pay a dividend.
What is the Price/Earnings (PE) ratio of ZYME?
ZYME does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).
What is the Short Interest ratio of ZYME stock?
The outstanding short interest for ZYME is 6.23% of its float.
ZYME Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ZYME. When comparing the yearly performance of all stocks, ZYME is one of the better performing stocks in the market, outperforming 84.96% of all stocks.
ZYME Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZYME. ZYME scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ZYME Financial Highlights
Over the last trailing twelve months ZYME reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS increased by -141.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.33% | ||
| ROE | -30.97% | ||
| Debt/Equity | 0 |
ZYME Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to ZYME. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 14.96% and a revenue growth 14.37% for ZYME